MTOR and breast cancer: The combination of mTOR inhibitor Everolimus (Eve) with the aromatase inhibitor Exemestane was observed to significantly increase progression free survival of BC patients treated with Exemestane as a single agent with hormonal receptor positive tumors (Bolero Trial) [13,14].